Answers are grounded in this paper and cite their sources.
Background Relapse rates following complete surgical resection (CSR) of pulmonary osteosarcoma recurrence remain high. We hypothesized that PD‐1 inhibition with nivolumab (Nivo) combined with epigenetic priming using azacitidine (5‐Aza) would be safe and augment systemic immune activation in patients with resectable pulmonary osteosarcoma relapse. Methods This Phase I trial sought to establish the recommended Phase II dose (RP2D) of perioperative Nivo/5‐Aza in patients ≤39 years old with isolated, resectable pulmonary osteosarcoma relapse. Three dose levels (DLs) were studied using a modified 3 + 3 design with dose‐limiting toxicities (DLTs) assessed from Day 1 of therapy to CSR. Patients received biweekly Nivo 3 mg/kg alone (DL1) or with 5‐Aza at 60 or 75 mg/m 2 /day (DL2 and DL3) in 28‐day cycles. Results Twenty patients received therapy; 18 were evaluable for DLTs. DL3 exceeded the maximum tolerated dose (Grade 3 vomiting, prolonged Grade 4 neutropenia). Common adverse events included anemia, neutropenia, and nausea. Seventeen patients (85%) reached CSR after neoadjuvant therapy. Median event‐free survival (EFS) was 3.3 months (95% confidence interval [CI]: 1.7–7.7 months), and median overall survival was 21.1 months (95% CI: 10.1–42.6 months). Combination therapy was associated with evidence of systemic immune activation, including increases in IFN‐γ, IL‐1α, IL‐1β, and CCL5. Conclusion The RP2D was Nivo 3 mg/kg and 5‐Aza 60 mg/m 2 /day on Days 1–5 and 8–9. The combination was feasible and tolerable. EFS was limited in the context of a Phase I trial. These findings provide safety, feasibility, and exploratory immunologic data to inform future immunotherapy trials in osteosarcoma.
No takes yet. Share an insight, caveat, or question.
Campbell et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: